Chemotherapy of advanced prostatic cancer with adriamycin, BCNU, and cyclophosphamide

Abstract

A phase II trial of Adriamycin, BCNU, and cyclophosphamide was performed in 29 patients with advanced prostatic carcinoma (Southeastern Cancer Study Group protocol SEG 76 PR 0102P). Therapy consisted of BCNU 100 mg/m2, plus cyclophosphamide, 300 mg/m2 i.v., on day 1, followed by Adriamycin, 30 mg/m2 i.v., on day 2. Therapy was repeated every four weeks. In 27 evaluable patients refractory to prior estrogen therapy, one patient had a complete response, six patients had partial responses, and two patients had objective improvement (complete plus partial response rate 26%, and overall response rate 33%). Responders had a median time to progression of disease of 5.5 months, compared with a median time to progression of 4.0 months for those patients with stable disease. The median survival of responders was 9.3 months, compared with 6.7 months for stable disease and 3.9 months for patients with progression. Patients with higher pretreatment performance status did not have higher response rates. No life-threatening toxicity was observed. Only five patients had nadir platelet counts below 50,000/mm3, and only six patients had nadir granulocyte counts below 750/mm3. This regimen palliates the effects of hormone-resistant metastatic prostatic carcinoma.

Chemosensitization of Carmustine with Maitake β-Glucan on Androgen-Independent Prostatic Cancer Cells: Involvement of Glyoxalase I

“…Such Gly-I inactivation may then help overcome drug resistance, leading to growth cessation and/or cell death in prostatic cancer cells. Moreover, clinical trials of BCNU on patients with PC were conducted more than 20 years ago (Presant et al, 1976(Presant et al, , 1980, and showed some promising outcomes. However, because no further studies have been reported since then, it is worthwhile to resume the investigation of BCNU to reevaluate its efficacy on prostatic cancer cells and to explore its cytotoxic mechanism.…”